This is the authors' abstract. We don't add key points for this paper.
Neither GEM FDR nor GEMOX resulted in substantially improved survival or symptom benefit over standard GEM in patients with advanced pancreatic cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Poplin et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: